Page 1 of 1
Q4: A report describing the lipophilicity aspects of five well-known PPARy-ligands, belonging to the thiazolidinedione (
Posted: Fri Jun 10, 2022 11:27 am
by correctanswer

- Q4 A Report Describing The Lipophilicity Aspects Of Five Well Known Ppary Ligands Belonging To The Thiazolidinedione 1 (14.6 KiB) Viewed 390 times

- Q4 A Report Describing The Lipophilicity Aspects Of Five Well Known Ppary Ligands Belonging To The Thiazolidinedione 2 (27.8 KiB) Viewed 390 times

- Q4 A Report Describing The Lipophilicity Aspects Of Five Well Known Ppary Ligands Belonging To The Thiazolidinedione 3 (27.8 KiB) Viewed 390 times
Q4: A report describing the lipophilicity aspects of five well-known PPARy-ligands, belonging to the thiazolidinedione (TZD) dass has recently appeared. Pioglitazone (PGZ) is shown below. FOR Explain Lipinski's rule of five and determine whether or not PGZ meets the criteria for oral bogp-1.31 bioavailability? Draw the predominant form of PGZ at PH 10 and 3.07 The chemical Ciglitazone (CGZ) reveals the following LogP CGZ 5.11 LogD74 463 Log D90 3.49 Why is the logp higher for CGZ than PGZ?
Of A report descritte lipophilicity aspects of five well-known PPA-ligands, belonging to the hiazolidinedione (TZD) class has recently appeared. Pioglitazone (PGZ) is shown below. POZ log p-3.33 Explain Lipinski's rule of five and determine whether or not PGZ meets the criteria for oral bioavailability? Draw the predominant form of PGZ at PH 10 and 3.0? PH=10 PH = 3 The chemical Ciglitazone (CGZ) reveals the following Logp LogD 7.4 4.63 CGZ Log D9.0 3.49 5.71 caz Why is the logp higher for CGZ than PGZ? replace pyridine with hyjor phobic hunchioned group. The logD2.5 of CGZ-5.71. Explain?